779 related articles for article (PubMed ID: 19734117)
21. Comparative activity of antiemetic drugs.
Jordan K; Schmoll HJ; Aapro MS
Crit Rev Oncol Hematol; 2007 Feb; 61(2):162-75. PubMed ID: 17208005
[TBL] [Abstract][Full Text] [Related]
22. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy.
Decker GM; DeMeyer ES; Kisko DL
J Support Oncol; 2006 Jan; 4(1):35-41, 52. PubMed ID: 16444851
[TBL] [Abstract][Full Text] [Related]
23. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
Trigg ME; Higa GM
J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
[TBL] [Abstract][Full Text] [Related]
25. Clinical practice guidelines on antiemetics in oncology.
Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
[TBL] [Abstract][Full Text] [Related]
26. Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting?
Sarcev T; Secen N; Zaric B; Milovancev A
J BUON; 2008; 13(3):333-9. PubMed ID: 18979546
[TBL] [Abstract][Full Text] [Related]
27. Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting.
Schwartzberg LS; Grunberg SM; Kris MG
Clin Adv Hematol Oncol; 2011 Nov; 9(11 Suppl 27):1-14; quiz 15-6. PubMed ID: 22362372
[TBL] [Abstract][Full Text] [Related]
28. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
Hsu ES
Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
[TBL] [Abstract][Full Text] [Related]
29. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
30. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
[TBL] [Abstract][Full Text] [Related]
31. Emerging treatments in chemotherapy-induced nausea and vomiting.
Grunberg SM; Slusher B; Rugo HS
Clin Adv Hematol Oncol; 2013 Feb; 11(2 Suppl 1):1-18; quiz 2 p following 18. PubMed ID: 23598819
[TBL] [Abstract][Full Text] [Related]
32. Optimising antiemetic therapy: what are the problems and how can they be overcome?
Aapro M
Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
[TBL] [Abstract][Full Text] [Related]
33. [New developments in the treatment of nausea and vomiting caused by chemotherapy].
de Wit R; van Alphen MM
Ned Tijdschr Geneeskd; 2003 Apr; 147(15):690-4. PubMed ID: 12722531
[TBL] [Abstract][Full Text] [Related]
34. Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
Saito M; Tsukuda M
Expert Opin Pharmacother; 2010 Apr; 11(6):1003-14. PubMed ID: 20307224
[TBL] [Abstract][Full Text] [Related]
35. Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines.
Yu S; Burke TA; Chan A; Kim HK; Hsieh RK; Hu X; Liang JT; Baños A; Spiteri C; Keefe DM
Support Care Cancer; 2015 Jan; 23(1):273-82. PubMed ID: 25115892
[TBL] [Abstract][Full Text] [Related]
36. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
[TBL] [Abstract][Full Text] [Related]
37. Antiemetic drugs.
Cranwell-Bruce L
Medsurg Nurs; 2009; 18(5):309-13; quiz 314. PubMed ID: 19927970
[No Abstract] [Full Text] [Related]
38. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
39. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations.
Jordan K; Sippel C; Schmoll HJ
Oncologist; 2007 Sep; 12(9):1143-50. PubMed ID: 17914084
[TBL] [Abstract][Full Text] [Related]
40. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009.
Jordan K; Roila F; Molassiotis A; Maranzano E; Clark-Snow RA; Feyer P;
Support Care Cancer; 2011 Mar; 19 Suppl 1():S37-42. PubMed ID: 20824481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
